U.S. markets close in 5 hours 50 minutes
  • S&P 500

    4,144.56
    +9.62 (+0.23%)
     
  • Dow 30

    33,958.22
    +136.92 (+0.40%)
     
  • Nasdaq

    13,791.83
    +5.56 (+0.04%)
     
  • Russell 2000

    2,200.39
    +12.18 (+0.56%)
     
  • Crude Oil

    61.76
    -0.91 (-1.45%)
     
  • Gold

    1,797.40
    +19.00 (+1.07%)
     
  • Silver

    26.48
    +0.64 (+2.46%)
     
  • EUR/USD

    1.2011
    -0.0030 (-0.25%)
     
  • 10-Yr Bond

    1.5590
    -0.0030 (-0.19%)
     
  • GBP/USD

    1.3910
    -0.0027 (-0.19%)
     
  • USD/JPY

    108.1330
    +0.0630 (+0.06%)
     
  • BTC-USD

    55,520.89
    -464.26 (-0.83%)
     
  • CMC Crypto 200

    1,277.14
    +14.18 (+1.12%)
     
  • FTSE 100

    6,898.61
    +38.74 (+0.56%)
     
  • Nikkei 225

    28,508.55
    -591.83 (-2.03%)
     

Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Intra-Cellular Therapies Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 10:00 am ET.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

CONTACT:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns
John Grimaldi
jgrimaldi@burnsmc.com
212-213-0006